Strides Pharma Subsidiary Secures FDA Approval for Chennai Facility.

Strides Pharma Science Limited announced today that its wholly-owned subsidiary, Strides Alathur Private Limited, has been granted an Establishment Inspection Report (EIR) by the U.S. Food and Drug Administration (USFDA) for its formulations facility in Alathur, Chennai. The EIR confirms the successful completion of a Good Manufacturing Practices (GMP) inspection conducted from April 1 to April 5, 2024.

The inspection outcome was classified by the USFDA as "Voluntary Action Indicated" (VAI). This facility, which specializes in the production of tablets and capsules for the U.S. and other regulated markets, plays a vital role in Strides’ current and future product offerings in the United States.

At 11:55 am on Monday, shares of Strides Pharma Science Limited were trading at ₹1,298.15, reflecting a decrease of ₹14.70, or 1.12%, on the NSE.

HBL